Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism
Cochrane Database of Systematic ReviewsPublished 25 October 1999
AGM van den Belt, MH Prins, A.W.A. Lensing, AA Castro, OAC Clark, AN Atallah
Citations107
SJR quartileQ1
SJR score1.62
SNIP2.04
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
LMWH significantly reduces the occurrence of major haemorrhage during initial treatment and overall mortality at follow up and is more effective than UFH for the initial treatment of VTE.
Abstract
Low molecular weight heparin is at least as effective as unfractionated heparin in preventing recurrent venous thromboembolism, and significantly reduces the occurrence of major haemorrhage during initial treatment and overall mortality at the end of follow-up. It can be adopted safely as the standard therapy for deep venous thrombosis, and studies comparing individual low molecular weight heparins are merited.
Keywords
MedicineHealth Professions
JNCI Journal of the National Cancer InstituteStatistical Aspects of the Analysis of Data From Retrospective Studies of Disease
14,860 Citations1959Nathan Mantel, William Haenszel
New England Journal of MedicineA Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1,717 Citations1998Hervé Decousus, Alain Leizorovicz +10 more
In high-risk patients with proximal deep-vein thrombosis, the initial beneficial effect of vena caval filters for the prevention of pulmonary embolism was counterbalanced by an excess of recurrent deep-vesin thROMBosis, without any difference in mortality.
New England Journal of MedicineA Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
1,198 Citations1996Mark Levine, Michael Gent +17 more
Low-molecular-weight heparin can be used safely and effectively to treat patients with proximal deep-vein thrombosis at home.
New England Journal of MedicineTreatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home
1,120 Citations1996Maria M.W. Koopman, Paolo Prandoni +14 more
In patients with proximal-vein thrombosis, treatment with low-molecular-weight heparin at home is feasible, effective, and safe.
New England Journal of MedicineLow-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
787 Citations1997The Columbus Investigators
Fixed-dose, subcutaneous low-molecular-weight heparin is as effective and safe as adjusted- dose, intravenous unfractionated Heparin for the initial management of venous thromboembolism, regardless of whether the patient has pulmonary embolism or a history of venOUS thrombolism.
New England Journal of MedicineA Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism
784 Citations1997Gérald Simonneau, Hervé Sors +10 more
Under the conditions of this study, initial subcutaneous therapy with the low-molecular-weight heparin tinzaparin appeared to be as effective and safe as intravenous unfractionated Heparin in patients with acute pulmonary embolism.
New England Journal of MedicineContinuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis
731 Citations1986Russell D. Hull, Gary E. Raskob +9 more
The results of this trial establish the efficacy of intravenous heparin in the treatment of proximal venous thrombosis and suggest a relation between the effectiveness ofHeparin and the levels of anticoagulation achieved; such a relation could explain the observed failure of the subcutaneous regimen.
New England Journal of MedicineSubcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
703 Citations1992Russell D. Hull, Gary E. Raskob +16 more
The LancetLow-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
673 Citations1992Michael T. Nurmohamed, Harry R. Büller +6 more
There is at present no convincing evidence that in general surgery patients LMWHs, compared with standard heparin, generate a clinically important improvement in the benefit to risk ratio, but LM WHs may be preferable for orthopaedic surgery patients, in view of the larger absolute risk reduction for venous thrombosis.
New England Journal of MedicineA Prospective Study of the Value of Monitoring Heparin Treatment with the Activated Partial Thromboplastin Time
665 Citations1972Dilip Basu, Alexander Gallus +2 more
Two hundred and thirty-four patients treated with continuous intravenous infusions of heparin were studied prospectively to seek a relation between the activated partial thromboplastin tim...
Annals of Internal MedicinePulmonary Angiography, Ventilation Lung Scanning, and Venography for Clinically Suspected Pulmonary Embolism with Abnormal Perfusion Lung Scan
654 Citations1983Hull Rd, J. Hirsh +10 more
The LancetComparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
588 Citations1992Paolo Prandoni, Mariarosa Carta +7 more
It is concluded that fixed-dose subcutaneous LMWH is at least as effective and safe as intravenous adjusted-dose heparin in the initial treatment of symptomatic proximal-vein thrombosis and since there is no need for laboratory monitoring with the LMWH regimen, patients with venous thromBosis can be treated at home.
New England Journal of MedicineHeparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous Thrombosis
511 Citations1990Russell D. Hull, Gary E. Raskob +7 more
It is concluded that a five-day course of heparin is as effective as a 10- day course in treating deep venous thrombosis and furthermore, using the shorter course would permit earlier discharge from the hospital and thus offer substantial cost savings.
New England Journal of MedicineAcenocoumarol and Heparin Compared with Acenocoumarol Alone in the Initial Treatment of Proximal-Vein Thrombosis
482 Citations1992Dees P. M. Brandjes, Harriët Heijboer +4 more
Patients with proximal-vein thrombosis require initial treatment with full-dose heparin, which can safely be combined with acenocoumarol therapy, and major bleeding complications were infrequent and comparable in the two groups.
CHEST JournalUnexpected High Prevalence of Silent Pulmonary Embolism in Patients with Deep Venous Thrombosis
311 Citations1989Menno V. Huisman, Harry R. Büller +5 more
Lung-scan detected asymptomatic pulmonary embolism occurs frequently in patients presenting with symptomatic deep venous thrombosis, and the majority of these emboli showed significant to complete resolution within one week of anticoagulant treatment.
The LancetSAFETY AND EFFICACY OF WARFARIN STARTED EARLY AFTER SUBMASSIVE VENOUS THROMBOSIS OR PULMONARY EMBOLISM
310 Citations1986Alexander Gallus, J. Tillett +3 more
Early warfarin treatment significantly shortened hospital stay by an average of 3.9 days (30%) in patients admitted solely because of VTE, and outpatient follow-up showed no excess recurrent VTE in either treatment group.
Thrombosis and HaemostasisHeparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance
254 Citations1992Edward Young, Martin H. Prins +2 more
Heparin dosage requirements vary widely among patients with venous thromboembolism, and the results indicate that reversible heparin neutralization due to binding to plasma proteins is a major determinant of the anticoagulant response to a fixed dose of standard Heparin 6 h post-treatment.
Archives of Internal MedicineSubcutaneous Low-Molecular-Weight Heparin Compared With Continuous IntravenoUnfractionated Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis
234 Citations1993Gérald Simonneau
This study confirmed, with the use of enoxaparin, other observations that low-molecular-weight heparin provides a real therapeutic advance in the treatment of deep vein thrombosis.
Thrombosis and HaemostasisComparison of Once-Daily Subcutaneous Fragmin® with Continuous Intravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis
212 Citations1994Per Lindmarker, Margareta Holmström +3 more
Fragmin® given s.c. once daily in a fixed dose adjusted for body weight, is no less effective or safe than a continuous infusion of UFH in the initial treatment of acute DVT.
European Journal of Clinical PharmacologyDose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin
184 Citations1990G.F. Handeland, Ulrich Abildgaard +2 more
The results indicate that plasma heparin concentration is more predictable using LMWH than UFH, and they point to definite advantages in the use of LMWH in a bodyweight adjusted dosage.
Statistics in MedicineAvoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews
181 Citations1987Rory Collins, Richard Gray +2 more
Future trials should take into account the results of any relevant overviews in their design, and should plan to obtain sufficient numbers of events to contribute substantially to such overviews, which implies the need for randomized trials that are much larger than is currently standard.
CirculationTreatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.
164 Citations1989J Albada, H K Nieuwenhuis +1 more
Low molecular weight heparin (Fragmin) given in adjusted, continuous, and intravenous doses is safe and effective as initial treatment of acute venous thromboembolism compared with Heparin, and a trend in risk reduction for bleeding is smaller than expected compared with animal studies.
Thrombosis and HaemostasisTwo Daily Subcutaneous Injections of Fragmin as Compared with Intravenous Standard Heparin in the Treatment of Deep Venous Thrombosis (DVT)
150 Citations1990Göran Bratt, W. Åberg +4 more
It is concluded that two daily sc Fragmin doses seem as effective and safe as continuous heparin as continuous infusion in the treatment of DVT of the leg.
Thrombosis and HaemostasisA Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis
148 Citations1991J. Ninet, Ph. Bachet +33 more
Subcutaneous CY 216 in fixed doses based only on body weight was more effective on the Arnesen and Marder phlebographic scores than continuous i.e. standard heparin with daily dose adjustment according to results of coagulation tests.
Thrombosis and HaemostasisSubcutaneous Low Molecular Weight Heparin versus Subcutaneous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis: a Polish Multicenter Trial
147 Citations1992S Łopaciuk, Alfred Jerzy Meissner +8 more
Subcutaneous fixed dose Fraxiparine is safe and at least as effective as subcutaneous adjusted UFH in the treatment of deep vein thrombosis and during a follow-up period of 3 months, two rethromboses had occurred in the UFH group and none in the Fraxine group.
Thrombosis and HaemostasisOnce-daily Subcutaneous Dalteparin, a Low Molecular Weight Heparin, for the Initial Treatment of Acute Deep Vein Thrombosis
138 Citations1996Jean‐Noël Fiessinger, María Fernanda López Fernández +5 more
Dalteparin administered once-daily at a fixed dose of 200 UI/kg is as effective and well-tolerated as UFH in patients with DVT below the inguinal ligament, and studies to investigate the possibility of using dALTeparin for the initial treatment of DVT in the outpatient setting are warranted.
Thrombosis and HaemostasisReplacing Inpatient Care by Outpatient Care in the Treatment of Deep Venous Thrombosis – An Economic Evaluation
92 Citations1998Angelique van den Belt, Martin H. Prins +4 more
The data suggest that outpatient management of patients with proximal venous thrombosis using low-molecular-weight heparin reduces resource utilisation and total treatment cost.
Journal of Internal MedicineA multicentre comparison of once‐daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
89 Citations1996K Luomanmäki, S. GRANKVIST +8 more
To compare the efficacy and safety of the low molecular weight heparin (LMWH) dalteparin with unfractionated heparins (UFH) in the acute treatment of DVT patients who had not previously received UFH.
HaemostasisTherapeutic Application of Subcutaneous Low-Molecular-Weight Heparin in Acute Venous Thrombosis
74 Citations2009Job Harenberg, K Huck +7 more
Patients presenting with acute deep-vein thrombosis were randomized in a prospective, controlled study to determine the safety and efficacy of a treatment with low-molecular-weight Heparin compared with unfractionated heparin.
HaemostasisIntravenous and Subcutaneous Administration of Fragmin in Deep Venous Thrombosis
42 Citations2009D. Lockner, Göran Bratt +3 more
Fragmin was as effective as UFH in preventing the progress of thrombosis in DVT and subcutaneous injections of Fragmin 2 times daily also appears to prevent the progression of thROMbosis effectively.
PubMedFrom unfractionated heparins to low molecular weight heparins.
29 Citations1990J. Hirsh
In preliminary studies, low molecular weight heparins appear to be as effective as unfractionated heparin in the treatment of venous thrombosis but larger studies are required using clinically relevant outcome measures.
Journal of International Medical ResearchDeep Vein Thrombosis of the Legs: New Therapy by Mean of Low Molecular Weight Heparins
24 Citations1988M Zanghì, V Morici +3 more
The anti-thrombotic effect of low molecular weight heparin was greater than for calcium hepar in patients with deep vein thrombosis and low molecular Weight Heparin improved maximum venous outflow in approximately half of the patients.
Thrombosis and HaemostasisSUBCUTANEOUS ADMINISTRATION OF A LOW MOLECULAR WEIGHT HEPARIN (CY 222) COMPARED WITH SUBCUTANEOUS ADMINISTRATION OF STANDARD HEPARIN IN PATIENTS WITH ACUTE DEEP VEIN THROMBOSIS
19 Citations1987R. Faivre, Eric Neuhart +4 more
Preliminary results suggested that sc administration of CY 222 and SH, both given by 2 daily injections, was equally effective in pts with acute DVT, and CY 222 seemed to be safer than SH.
Thrombosis and HaemostasisEFFICACY AND SAFETY OF A LOW MOLECULAR WEIGHT HEPARIN (LMW-HEPARIN SANDOZ) IN PATIENTS WITH DEEP VEIN THROMBOSIS
12 Citations1987G Vogel, M Machulik
The result suggest that LMWH Sandoz and UFH were equally effecetive on thrombus reduction whereas hemorrgic complications were more common with UFH than with LMWH.